{"pmid":32302280,"title":"Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.","text":["Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.","As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.(2) We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.","West J Emerg Med","Brown, Cortlyn","Noble, Jeanne","Coralic, Zlatan","32302280"],"abstract":["As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.(2) We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective."],"journal":"West J Emerg Med","authors":["Brown, Cortlyn","Noble, Jeanne","Coralic, Zlatan"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302280","week":"202016|Apr 13 - Apr 19","doi":"10.5811/westjem.2020.3.47328","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664357978701037568,"score":8.233237,"similar":[{"pmid":32243270,"title":"Potential therapeutic agents against COVID-19: What we know so far.","text":["Potential therapeutic agents against COVID-19: What we know so far.","The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.","J Chin Med Assoc","Lu, Chih-Chia","Chen, Mei-Yu","Chang, Yuh-Lih","32243270"],"abstract":["The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19."],"journal":"J Chin Med Assoc","authors":["Lu, Chih-Chia","Chen, Mei-Yu","Chang, Yuh-Lih"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243270","week":"202014|Mar 30 - Apr 05","doi":"10.1097/JCMA.0000000000000318","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["tocilizumab","Ribavirin","Hydroxychloroquine","Ritonavir","Chloroquine","sarilumab","favipiravir","Lopinavir"],"_version_":1663352135701495808,"score":104.7617},{"pmid":32300496,"pmcid":"PMC7158591","title":"Coronavirus Disease: A Review of a New Threat to Public Health.","text":["Coronavirus Disease: A Review of a New Threat to Public Health.","In December 2019, several patients from Wuhan, China were admitted to hospitals with symptoms of pneumonia. As the number of patients presenting with similar symptoms started to rise, the causative agent was eventually isolated from samples. It was initially called the 2019 novel coronavirus (2019-nCoV) and has been recently relabelled as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the disease it causes has been named coronavirus disease 2019 (COVID-19). Over the next few weeks, the virus spread from Wuhan to affect different provinces in China and, after a few months, it is now present in 109 countries. As of March 10, 2020, there have been 113,702 confirmed cases globally, and 4,012 deaths have been registered. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are multiple drug trials going on with some positive results. However, since no vaccine is available, the best way to combat the virus is by preventive methods.","Cureus","Ramphul, Kamleshun","Mejias, Stephanie G","32300496"],"abstract":["In December 2019, several patients from Wuhan, China were admitted to hospitals with symptoms of pneumonia. As the number of patients presenting with similar symptoms started to rise, the causative agent was eventually isolated from samples. It was initially called the 2019 novel coronavirus (2019-nCoV) and has been recently relabelled as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the disease it causes has been named coronavirus disease 2019 (COVID-19). Over the next few weeks, the virus spread from Wuhan to affect different provinces in China and, after a few months, it is now present in 109 countries. As of March 10, 2020, there have been 113,702 confirmed cases globally, and 4,012 deaths have been registered. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are multiple drug trials going on with some positive results. However, since no vaccine is available, the best way to combat the virus is by preventive methods."],"journal":"Cureus","authors":["Ramphul, Kamleshun","Mejias, Stephanie G"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32300496","week":"202016|Apr 13 - Apr 19","doi":"10.7759/cureus.7276","keywords":["coronavirus disease","covid-19","sars-cov-2","severe acute respiratory syndrome coronavirus 2","wuhan"],"source":"PubMed","topics":["Prevention","Diagnosis","Treatment"],"weight":1,"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664357978474545152,"score":100.743706},{"pmid":32281213,"title":"A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).","text":["A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).","OBJECTIVE: The pandemic Coronavirus Disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID-19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID-19. METHODS: PubMed, EMBASE, ClinicalTrials.gov, ICTRP, and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies) until 30 March 2020. The available literature was critically appraised. RESULTS: A total of 45 articles were screened and five (three in vitro pre-clinical studies and two clinical opinions) were included. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID-19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available. CONCLUSION: Although pre-clinical results are promising, till date, there is dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID-19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID-19 needs to be thoroughly evaluated in observational studies or high quality randomized controlled studies.","Int J Rheum Dis","Shah, Sanket","Das, Saibal","Jain, Avinash","Misra, Durga Prasanna","Negi, Vir Singh","32281213"],"abstract":["OBJECTIVE: The pandemic Coronavirus Disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID-19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID-19. METHODS: PubMed, EMBASE, ClinicalTrials.gov, ICTRP, and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies) until 30 March 2020. The available literature was critically appraised. RESULTS: A total of 45 articles were screened and five (three in vitro pre-clinical studies and two clinical opinions) were included. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID-19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available. CONCLUSION: Although pre-clinical results are promising, till date, there is dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID-19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID-19 needs to be thoroughly evaluated in observational studies or high quality randomized controlled studies."],"journal":"Int J Rheum Dis","authors":["Shah, Sanket","Das, Saibal","Jain, Avinash","Misra, Durga Prasanna","Negi, Vir Singh"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281213","week":"202016|Apr 13 - Apr 19","doi":"10.1111/1756-185X.13842","keywords":["COVID-19","Prevention","SARS-CoV-2","chloroquine","high-risk","hydroxychloroquine"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664182200725143553,"score":98.49535},{"pmid":32251618,"title":"Current Drugs with Potential for Treatment of COVID-19: A Literature Review.","text":["Current Drugs with Potential for Treatment of COVID-19: A Literature Review.","PURPOSE: SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence. The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs. CONCLUSION: All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use.","J Pharm Pharm Sci","Md Insiat Islam Rabby","32251618"],"abstract":["PURPOSE: SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence. The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs. CONCLUSION: All examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trial to be suitable for clinical use."],"journal":"J Pharm Pharm Sci","authors":["Md Insiat Islam Rabby"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251618","week":"202015|Apr 06 - Apr 12","doi":"10.18433/jpps31002","source":"PubMed","locations":["Chinese","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352136269824000,"score":97.88597},{"pmid":32219057,"pmcid":"PMC7094941","title":"The SARS-CoV-2 Vaccine Pipeline: an Overview.","text":["The SARS-CoV-2 Vaccine Pipeline: an Overview.","Purpose of Review: The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19). Recent Findings: Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines. Summary: Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time.","Curr Trop Med Rep","Chen, Wen-Hsiang","Strych, Ulrich","Hotez, Peter J","Bottazzi, Maria Elena","32219057"],"abstract":["Purpose of Review: The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19). Recent Findings: Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines. Summary: Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time."],"journal":"Curr Trop Med Rep","authors":["Chen, Wen-Hsiang","Strych, Ulrich","Hotez, Peter J","Bottazzi, Maria Elena"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219057","week":"202013|Mar 23 - Mar 29","doi":"10.1007/s40475-020-00201-6","keywords":["COVID-19","Coronavirus","RBD","Receptor binding domain","Wuhan virus"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352135031455744,"score":97.737564}]}